|UNITED STATES
        SECURITIES AND EXCHANGE COMMISSION
        WASHINGTON, DC 20549
|-------------------------------------------------------------------------------------

________________________________



FORM 10-Q/A

(Amendment No. 1)

________________________________



| | x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.
| | - | ----------------------------------------------------------------------------------------



For the quarterly period ended March
31, 2016



Or



| |  ̈ | TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.
| | - | ------------------------------------------------------------------------------------------



For the transition period from _____________to
_____________



Commission File Number: 333-198073

________________________________

Second Sight Medical Products, Inc.

(Exact name of registrant as specified
in its charter)



________________________________



|California
        (State or other jurisdiction of
        incorporation or organization) |  | 02-0692322
        (IRS Employer
        Identification No.)
|----------------------------------------------------------------------------------------- |  | ------------------------------------------------------------



12744 San Fernando Road, Suite 400

Sylmar, California 91342

(818) 833-5000

(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)

________________________________



Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. YesxNo ̈



Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YesxNo ̈



Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule
12b-2 of the Exchange Act. (Check one):



|Large accelerated filer
        
        Non-accelerated filer |  ̈
        
         ̈ | (Do not check if a smaller reporting company) | Accelerated filer
        
        Smaller reporting company | x
        
         ̈
|-------------------------------------------------------------- | -------------------- | --------------------------------------------- | ------------------------------------------------------------ | --------------------



|Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2) | Yes ̈ | Nox
|-------------------------------------------------------------------------------------------------------- | ---- | ---



|As of August 5, 2016, the registrant had 42,199,454 shares of common stock outstanding.
|---------------------------------------------------------------------------------------











EXPLANATORY NOTE



Second Sight
Medical Products, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”)
for the purpose of (1) amending Item 4 of Part I in its entirety and (2)re-filingExhibits
31.1 and 31.2 to include a portion of the text required in paragraph 4 of the Section 302 certifications (specifically, a portion
of the introductory language of paragraph 4), which was inadvertently omitted from the Section 302 certification included with
the original Form 10-Q filed with the Securities and Exchange Commission on May 6, 2016 (the “Original Filing”).



As required by Rule 12b-15 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), we are also filing new certifications of our principal executive
officer and principal financial officer as exhibits to this Amendment. This Amendment should be read in conjunction with the Original
Filing, which continues to speak as of the date of the Original Filing. Except as specifically noted above, this Amendment does
not modify or update disclosures in the Original Filing. Accordingly, this Amendment does not reflect events occurring after the
filing of the Original Filing or modify or update any other disclosures.



Except as described above, no other information
in the Form 10-Q has been changed or updated and this Amendment No. 1 to the Form 10-Q continues to speak as of the date of
the Original Filing. This Amendment No. 1 is part of the Original Filing and should be read in conjunction with the Form 10-Q.
Other events occurring after the filing of the Original Filing or other disclosures necessary to reflect subsequent events have
been or will be addressed in other reports filed with or furnished to the SEC subsequent to the date of the Original Filing.



PART I – FINANCIAL INFORMATION



ITEM 4. CONTROLS AND PROCEDURES





Evaluation of Disclosure Controls and Procedures



Our management, including our Chief Executive Officer and our
Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2016. The term “disclosure
controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures
of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or
submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s
rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that
information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated
and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate
to allow timely decisions regarding required disclosure. As of March 31, 2016, based on the evaluation of these disclosure controls
and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive
Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective.



Remediation Plan



As of March 31, 2016, there were control deficiencies which constituted
material weaknesses in our internal control over financial reporting. Management has taken, and is taking steps to strengthen our
internal control over financial reporting. Specifically:



| | · | Control over Financial Reporting. We have implemented additional processes and procedures surrounding the closing process, including the preparation and review of journal entries and account reconciliations to ensure accuracy of financial reporting including timely account reconciliation review. We have adopted further procedures and review processes surrounding revenue, deferred revenue, inventory and stock-based compensation that will reduce end of accounting period adjustments. We also plan to implement a software application that will help us to automate controls surrounding the closing process, including the review of journal entries and account reconciliations.
| | - | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | · | Control over Tracking of Back-up Prosthesis Units. We conducted a multi-departmental review of how we track our back-up prosthesis units and implemented a manual monthly reconciliation procedure among accounting, billing and inventory management. During the second quarter of 2016, we will be  implementing a software solution that allows us to track back-up units that are sent to customers and facilitates proper tracking and accounting for these units. Additionally, we continue to perform a manual reconciliation of the back-up units.
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



While we have taken certain actions
to address the material weaknesses identified, additional measures may be necessary as we work to improve the overall effectiveness
of our internal controls over financial reporting. Through the actions in the remediation plan reported in our Annual Report on
Form 10-K for the year ended December 31, 2015, as amended, and new actions which have since been initiated, we believe that we
are addressing the deficiencies that affected our internal control over financial reporting for the year then ended however we
have not completed all of the corrective processes and procedures as contemplated herein for the identified material weaknesses.
Until the remediation plan is fully implemented and operating for a sufficient period of time, we will not be able to conclude
that the material weaknesses have been remediated. We will continue to monitor and assess our remediation activities to address
the material weaknesses discussed above through remediation as soon as practicable and to provide reasonable assurance that they
will prevent as detect material error in the financial statements.



2







Changes in Internal Control over Financial Reporting



Other than changes that have been enacted pursuant to our remediation
plan, there were no changes in our internal control over financial reporting during the quarter ended March 30, 2016 that materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.



Inherent Limitations on Effectiveness of Controls



Because of the inherent limitations of internal control over
financial reporting, including the possibility of collusion or improper management override of controls, material misstatements
due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness
of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



ITEM 6. EXHIBITS



See the Exhibit Index following the signature page to this Quarterly
Report on Form 10-Q/A for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by
reference.



3







SIGNATURES



Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



|                     | Second Sight Medical Products, Inc.
        (Registrant)
        
        /s/ Jonathan Will McGuire                                           
|-------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------
|Date: August 8, 2016 | Jonathan Will McGuire
        Chief Executive Officer and Director
        (Principal Executive Officer)
        
        /s/ Thomas B. Miller
|Date: August 8, 2016 | Thomas B. Miller
        Chief Financial Officer
        (Principal Financial and Accounting Officer)                                         



4







EXHIBIT INDEX



|Exhibit
        No. |  | Description                                                                                                                                              
|------------------- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------
|                    |  |                                                                                                                                                          
|31.1                |  | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
|                    |  |                                                                                                                                                          
|31.2                |  | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.



5